- TheNeedle.AI
- Posts
- MultiOmic Health Raises $6.2 Million to Fight Metabolic Syndrome - The Silent Killer
MultiOmic Health Raises $6.2 Million to Fight Metabolic Syndrome - The Silent Killer
MultiOmic aims to tackle the huge unmet medical need for precision medicines for metabolic syndrome-related conditions through its MOHSAIC® platform
TheNeedleAI Team
May 04, 2023
WHO MultiOmic Health is an AI-enabled drug discovery company.
WHAT MultiOmic Health will use machine learning and AI techniques to analyze complex patient data to discover unique treatment concepts for each metabolic syndrome disease variant.
WHY The precision therapeutics discovery platform aims to demonstrate proof-of-concept for MOHSAIC® in diabetic kidney disease, which accounts for an estimated $300 billion annually in global healthcare costs.
FUNDING MultiOmic Health began operations in May 2021 and has raised a total of $8.6 million, including a previous round led by Fifty Years. The seed extension funding round of $6.2M was led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures, and Verve Ventures.
CUSTOMER TRACTION MultiOmic Health aims to bring the immense benefits of precision medicine to metabolic syndrome patients, which is the most significant cause of death globally.
KEY TAKEAWAY MultiOmic Health's MOHSAIC® platform offers a unique opportunity to tackle metabolic syndrome-related conditions affordably with the right tools. Through innovations at the intersection of tech and bio, investors can see tremendous potential in this space.
We couldn’t be more bullish about the transformational impact that innovations at the intersection of tech and bio are having on patients.